MARKET

VIR

VIR

Vir Biotechnology, Inc.
NASDAQ
10.81
-0.29
-2.57%
Opening 15:03 09/24 EDT
OPEN
11.02
PREV CLOSE
11.09
HIGH
11.16
LOW
10.36
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
11.94
52 WEEK LOW
4.815
MARKET CAP
1.83B
P/E (TTM)
-5.8048
1D
5D
1M
3M
1Y
5Y
1D
Vir Biotechnology (VIR) Receives a Rating Update from a Top Analyst
TipRanks · 3d ago
Weekly Report: what happened at VIR last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at VIR last week (0907-0911)?
Weekly Report · 09/14 10:21
Weekly Report: what happened at VIR last week (0831-0904)?
Weekly Report · 09/07 10:15
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Barchart · 08/31 15:05
Weekly Report: what happened at VIR last week (0824-0828)?
Weekly Report · 08/31 10:22
Weekly Report: what happened at VIR last week (0817-0821)?
Weekly Report · 08/24 10:23
Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
TipRanks · 08/19 16:30
More
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. It also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Its key product candidates include Elebsiran (VIR-2218); Tobevibart (VIR-3434); VIR-5818; VIR-5525, and VIR-5500. These molecules leverage the PRO-XTEN masking technology with TCEs targeting CD3 on T-cells and HER2, PSMA and EGFR, respectively, on tumor cells. Elebsiran is an investigational hepatitis B virus (HBV)-targeted small interfering RNA that reduces hepatitis B surface antigen (HBsAg). Tobevibart is an investigational neutralizing monoclonal antibody that has been engineered for immune engagement and targets a conserved region on the HBsAg.

Webull offers Vir Biotechnology Inc stock information, including NASDAQ: VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.